June 5, 2024

LUND, Sweden – Cellevate AB, an innovative biotech company developing the next generation of cell culture systems designed to revolutionize biomanufacturing, is pleased to announce the appointment of Dr. Christel Fenge as Strategic Advisor. Dr. Fenge brings over 30 years of experience in various leadership roles across the bioprocessing and biopharmaceutical industry. Dr. Fenge previously served as Vice President, R&D Bioprocess at Cytiva with responsibility for upstream and downstream product development and Vice President, Marketing and Product Management Fermentation Technologies at Sartorius. Additionally, Dr. Christel Fenge served as General Manager of Recipharm Biologics, a mid-sized CMO, and held senior management positions in biopharmaceutical development at AstraZeneca. Her industrial career began in cell culture process development at Pharmacia & Upjohn, where she contributed to the development of Refacto™. Dr. Christel Fenge received her doctorate in Biochemistry from the University of Hanover, Germany. Since September 2023, she has been working as an independent Counsel and Advisor to the bioprocess industry.

“I am excited by the great opportunity that the Cellevate cell culture technology offers for the efficient manufacture of novel cell and gene therapies”, says Dr. Christel Fenge.

“We are thrilled to welcome Dr. Christel Fenge as an advisor to Cellevate. Dr. Fenge brings extensive expertise in product development in both upstream and downstream bioprocessing, along with a proven track record of management and marketing within the biopharmaceutical industry. Her valuable insights will greatly contribute to our product validation program for the commercial launch of Cellevat3d™ nanofiber microcarriers and the market introduction of other nanotechnology based products in our pipeline”, says Laura Chirica, CEO Cellevate.

More information about Cellevate’s Scientific & Industrial Advisory Board members.

For more information, please contact:
Laura Chirica, PhD
CEO Cellevate
Email: laura.chirica@cellevate.com

About Cellevate
Cellevate is a spin out from NanoLund – a world leading nanomaterial academic center, at Lund University in Sweden. The company develops and markets products based on a proprietary nanofiber-based platform – the Cellevat3d™ – a game-changing, green and sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of nanofiber materials – “microcarriers” – with unparalleled surface area for cell growth, reproducibility and customization, which ultimately lead to an improved biomanufacturing productivity and process economy. Cellevat3d™ nanofiber microcarriers products are designed as an integrated part of upstream bioprocess solutions, starting with laboratory testing of cell lines followed by pilot and large-scale batch production of gene therapies. Cellevat3d™ nanofiber microcarriers launch will be in the second half of 2024.

For more information, please visit www.cellevate.com.